Navigation Links
Study Shows How Defective DNA Repair Triggers Two Neurological Diseases

St. Jude scientists' findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases

MEMPHIS, Tenn., Jan. 14 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have teased apart the biological details distinguishing two related neurological diseases--ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).

Both disorders arise from defects in a central component of the cell's machinery that repairs damaged DNA, but each disease presents with distinct pathologies. Defects in DNA repair dramatically increase the risk of cancer, which is found in NBS. However, NBS is also characterized by the occurrence of small brain size, or microcephaly, while in contrast, ATLD causes predominantly neurodegeneration.

The research involved the use of mouse models of each the diseases to analyze how the gene defects in ATLD and NBS give rise to the different pathologies. The researchers published their findings in the Jan.15, 2009, issue of the journal Genes & Development.

"Besides shedding light on the rare diseases, the findings may also help to understand how defective DNA repair can selectively affect different organs and how this leads to cancer in some situations," said Peter McKinnon, Ph.D., associate member of the St. Jude Department of Genetics and Tumor Cell Biology and the paper's senior author.

To explore the differences between ATLD and NBS, the researchers used mice engineered to have defects in the causative genes, which produce two proteins that help form a critical component of the DNA repair machinery, called the MRN complex. The MRN complex zeroes in on broken DNA segments and attaches to them. It then recruits another important DNA repair protein, called ATM, to launch the repair process. However, if the damage is too severe, ATM may also trigger programmed cell death called apoptosis. "It happens that defects in ATM also lead to a disease similar to ATLD, highlighting the connections between diseases resulting from defects in this DNA repair pathway," McKinnon said.

The mice engineered to mimic ATLD, like their human counterparts, had defective genes that produce a protein called Mre11; while NBS mice were engineered to have defects in the gene for the protein called Nbs1.

In their experiments, the researchers produced increased DNA-damage stress in the two types of engineered mice, either by using radiation or knocking out a key enzyme that stitches together broken DNA ends.

The researchers then compared the resulting pathologies in the two types of mice. The scientists found that the brain cells of the ATLD mice but not the NBS mice showed a resistance to apoptosis, meaning that the DNA-damaged cells were more likely to survive, even when crippled. Such cells would ultimately die, however, producing the neurodegeneration characteristic of ATLD in humans. In contrast, the NBS mice showed normal apoptosis, but because fewer brain cells survived, developed significantly smaller brains, like their human counterparts.

"Thus, these findings have allowed us to understand how these different mutations in this one DNA repair complex can lead to different neuropathological outcomes," McKinnon said. The findings could also lead to understanding how carriers of the disease genes are more prone to cancer.

"There is a suspicion that people who carry these mutations may be predisposed to cancer and also more susceptible to chemotherapy agents or even to standard X-rays," McKinnon said. "Those agents induce the type of DNA damage that requires the MRN complex and ATM for repair. More generally, studies of the MRN complex and ATM are fundamental to understanding how to prevent changes to DNA that lead to cancer.

"Understanding more about how these proteins signal and interact, and how different cells in the body transduce the DNA damage signal, is of fundamental biological importance," McKinnon said. "This knowledge is necessary not only for understanding DNA repair diseases but for understanding the broader implications of maintaining of the stability of DNA."

Other authors of this paper include Erin Shull, Youngsoo Lee, Jingfeng Zhao and Helen Russell (St. Jude); John Petrini and Travis Stracker (Memorial Sloan Kettering Cancer Center and Cornell University Graduate School of Medical Sciences); and Hironobu Nakane (formerly of St. Jude).

This research was supported in part by the National Institutes of Health, the National Cancer Institute and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit

SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
3. VA-NIH Study Offers Hope for Parkinsons Patients
4. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
5. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
8. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
9. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
10. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
11. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
Post Your Comments:
(Date:11/25/2015)... announced the issue of United States patent No. 9,192,509  entitled: " Methods ... the company,s AVACEN 100 dry heat therapy medical device and specific methods of use, referred to ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, announced ... Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and nationally ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... cancer, I found that regular bras were incredibly uncomfortable," said an inventor from ... specialized bra." , She developed the patent-pending RECOVERY BRA for added comfort and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
Breaking Medicine News(10 mins):